ACZONE DIN 02281074
Health Canada record
| Active ingredient(s) | DAPSONE 5 % |
|---|---|
| Dosage form | Gel |
| Route | Topical |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | D10AX05 DAPSONE |
| Original market date | 21-Oct-2011 |
| Current status date | 04-Jun-2020 |
| Source | Health Canada DPD |
Establishment licence of the holder
Bausch Health Companies Inc. — licence 101880, currently licensed, last inspection rating C (2026-06-01).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing DAPSONE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02481227 | MAR-DAPSONE | MARCAN PHARMACEUTICALS INC | Tablet | DAPSONE 100 MG | Marketed |
| 02484625 | TARO-DAPSONE | TARO PHARMACEUTICALS INC | Tablet | DAPSONE 100 MG | Approved |
| 00002526 | AVLOSULFON TAB 100MG | AYERST LABORATORIES | Tablet | DAPSONE 100 MG | Cancelled Post Market |
| 02041510 | DAPSONE | EVEREST LIFE SCIENCES LLC | Tablet | DAPSONE 100 MG | Dormant |
| 02489058 | RIVA-DAPSONE | LABORATOIRE RIVA INC. | Tablet | DAPSONE 100 MG | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 23723 | 2020-06-04 | New Drug Submission (NDS) | Administrative: Change in Product Ownership |
| 12390 | 2011-06-02 | New Drug Submission (NDS) | Manufacturer name change |
| 9868 | 2008-11-04 | New Drug Submission (NDS) | MANUFACTURER NAME CHANGE |
| 8028 | 2006-06-15 | New Drug Submission (NDS) |
International API supply for DAPSONE
5 valid EDQM Certificates of Suitability from 5 holders. 12 active FDA Drug Master Files.
Request a quote for ACZONE